Figures & data
Figure 1. The figure represents the time-line for the study. Men in the NEO group were screened and then randomized (E2 versus PL) 3 weeks after their initial LHRH-A injection (baseline), and men in the EST group were randomized 3 weeks after initial screening.
![Figure 1. The figure represents the time-line for the study. Men in the NEO group were screened and then randomized (E2 versus PL) 3 weeks after their initial LHRH-A injection (baseline), and men in the EST group were randomized 3 weeks after initial screening.](/cms/asset/0ef8cbb4-bfbd-4fb2-96b5-cd7cfb9978d4/itam_a_295199_f0001_b.gif)
Table I. Baseline characteristics of study subjects.
Table II. Changes in clotting factors and inflammatory markers at baseline and after 9 weeks of E2 treatment.
Table III. Changes in inflammatory markers in 12 subjects 3 weeks after initial LHRH-A injection.